Posted by Michael Wonder on 21 Mar 2025
Novartis receives third FDA approval for oral Fabhalta (iptacopan) – the first and only treatment approved in C3 glomerulopathy
20 March 2025 - Phase 3 study showed sustained proteinuria reduction at one year with favourable safety.
Novartis today announced that oral Fabhalta (iptacopan) has received US FDA approval for the treatment of adults with C3 glomerulopathy, to reduce proteinuria, making it the first and only treatment approved for this condition.
